P W A Janssen1,2, T O Bergmeijer1,2, T C Godschalk1,2, T T D Le1,2, N J Breet1,2, J C Kelder1, C M Hackeng2,3, J M Ten Berg1,2. 1. Department of Cardiology, St Antonius Hospital, Nieuwegein, the Netherlands. 2. St Antonius Center for Platelet Function Research, St Antonius Hospital, Nieuwegein, the Netherlands. 3. Department of Clinical Chemistry, St Antonius Hospital, Nieuwegein, the Netherlands.
Abstract
Essentials Platelet reactivity is correlated with thrombotic risk after percutaneous coronary intervention (PCI). Hematocrit (HCT) is associated with platelet reactivity as measured with the VerifyNow P2Y12 assay. We tested a formula proposed to correct VerifyNow measurements for HCT in 978 PCI patients. Correcting platelet reactivity for HCT did not improve the prediction of thrombotic events after PCI. SUMMARY: Background High on-treatment platelet reactivity is predictive for the occurrence of atherothrombotic events following percutaneous coronary interventions (PCIs). A low hematocrit (HCT) value is associated with higher platelet reactivity values, expressed in P2Y12 reaction units (PRU), as measured with the VerifyNow P2Y12 assay. However, it is suggested that this is only an in vitro phenomenon. Objective To determine whether adjusting PRU for HCT improves the predictive value for thrombotic events following PCI. Material and methods The VerifyNow P2Y12 assay was performed in clopidogrel-treated patients undergoing non-urgent PCI included in a prospective cohort study. PRU values were corrected for HCT with a formula proposed in recent literature. Receiver operating characteristic (ROC) curves were made to determine the optimal cut-off values to predict the occurrence of the primary endpoint, a composite of all-cause death and non-fatal myocardial infarction, stent thrombosis and ischemic stroke, during 1 year of follow-up. The chi-squared test was performed to determine whether correcting PRU for HCT improved the prediction of the primary endpoint. Results A total of 978 patients were analyzed. A negative correlation between PRU and HCT was observed (R2 = 0.104). The optimal cut-off value for the corrected PRU was 215. ROC analyses showed that prediction of the primary endpoint did not differ for the corrected PRU (area under the curve, 0.61; sensitivity, 0.57; specificity, 0.64) and the uncorrected PRU (area under the curve, 0.61; sensitivity, 0.69; specificity, 0.53). Conclusion Correcting PRU for HCT does not improve the prediction of thrombotic events following PCI.
Essentials Platelet reactivity is correlated with thrombotic risk after percutaneous coronary intervention (PCI). Hematocrit (HCT) is associated with platelet reactivity as measured with the VerifyNow P2Y12 assay. We tested a formula proposed to correct VerifyNow measurements for HCT in 978 PCI patients. Correcting platelet reactivity for HCT did not improve the prediction of thrombotic events after PCI. SUMMARY: Background High on-treatment platelet reactivity is predictive for the occurrence of atherothrombotic events following percutaneous coronary interventions (PCIs). A low hematocrit (HCT) value is associated with higher platelet reactivity values, expressed in P2Y12 reaction units (PRU), as measured with the VerifyNow P2Y12 assay. However, it is suggested that this is only an in vitro phenomenon. Objective To determine whether adjusting PRU for HCT improves the predictive value for thrombotic events following PCI. Material and methods The VerifyNow P2Y12 assay was performed in clopidogrel-treated patients undergoing non-urgent PCI included in a prospective cohort study. PRU values were corrected for HCT with a formula proposed in recent literature. Receiver operating characteristic (ROC) curves were made to determine the optimal cut-off values to predict the occurrence of the primary endpoint, a composite of all-cause death and non-fatal myocardial infarction, stent thrombosis and ischemic stroke, during 1 year of follow-up. The chi-squared test was performed to determine whether correcting PRU for HCT improved the prediction of the primary endpoint. Results A total of 978 patients were analyzed. A negative correlation between PRU and HCT was observed (R2 = 0.104). The optimal cut-off value for the corrected PRU was 215. ROC analyses showed that prediction of the primary endpoint did not differ for the corrected PRU (area under the curve, 0.61; sensitivity, 0.57; specificity, 0.64) and the uncorrected PRU (area under the curve, 0.61; sensitivity, 0.69; specificity, 0.53). Conclusion Correcting PRU for HCT does not improve the prediction of thrombotic events following PCI.
Authors: Dagmar F Hernandez-Suarez; Hector Núñez-Medina; Stuart A Scott; Angel Lopez-Candales; Jose M Wiley; Mario J Garcia; Kyle Melin; Karid Nieves-Borrero; Christina Rodriguez-Ruiz; Lorraine Marshall; Jorge Duconge Journal: Drug Metab Pers Ther Date: 2018-03-28
Authors: J W Zhang; W W Liu; Timothy A McCaffrey; X Q He; W Y Liang; X H Chen; X R Feng; Sidney W Fu; M L Liu Journal: Clin Interv Aging Date: 2017-08-10 Impact factor: 4.458
Authors: Dagmar F Hernandez-Suarez; Mariana R Botton; Stuart A Scott; Matthew I Tomey; Mario J Garcia; Jose Wiley; Pedro A Villablanca; Kyle Melin; Angel Lopez-Candales; Jessicca Y Renta; Jorge Duconge Journal: Pharmgenomics Pers Med Date: 2018-06-08
Authors: Shefali Setia Verma; Thomas O Bergmeijer; Li Gong; Jean-Luc Reny; Joshua P Lewis; Braxton D Mitchell; Dimitrios Alexopoulos; Daniel Aradi; Russ B Altman; Kevin Bliden; Yuki Bradford; Gianluca Campo; Kiyuk Chang; John H Cleator; Jean-Pierre Déry; Nadia P Dridi; Israel Fernandez-Cadenas; Pierre Fontana; Meinrad Gawaz; Tobias Geisler; Gian Franco Gensini; Betti Giusti; Paul A Gurbel; Willibald Hochholzer; Lene Holmvang; Eun-Young Kim; Ho-Sook Kim; Rossella Marcucci; Joan Montaner; Joshua D Backman; Ruth E Pakyz; Dan M Roden; Elke Schaeffeler; Matthias Schwab; Jae Gook Shin; Jolanta M Siller-Matula; Jurriën M Ten Berg; Dietmar Trenk; Marco Valgimigli; John Wallace; Ming-Shien Wen; Michiaki Kubo; Ming Ta Michael Lee; Ryan Whaley; Stefan Winter; Teri E Klein; Alan R Shuldiner; Marylyn D Ritchie Journal: Clin Pharmacol Ther Date: 2020-07-09 Impact factor: 6.875